



Market Announcement

25 August 2023

Avecho Biotechnology Limited (ASX: AVE) – Suspension from Quotation

Description

The securities of Avecho Biotechnology Limited ('AVE') will be suspended from quotation immediately under Listing Rule 17.2, at the request of AVE, pending the release of an announcement regarding a capital raising.

Issued by

Melissa Kostopoulos
Adviser, Listings Compliance

ASX Announcement

25 August 2023

ASX Market Announcements
ASX Limited
Level 4
525 Collins Street, Rialto, North Tower
Melbourne VIC 3000

By email only: melissa.kostopoulos@asx.com.au
tradinghaltsmelbourne@asx.com.au

Dear Melissa,

REQUEST FOR VOLUNTARY SUSPENSION

Avecho Biotechnology Limited (ASX: AVE) (**the Company**) requests an immediate suspension of the Company's ordinary shares quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.2.

The voluntary suspension is requested pending an announcement by the Company to the market in relation to a capital raising as set out in the trading halt request dated 23 August 2023 (**stated purpose**).

In accordance with ASX Listing Rule 17.2, the Company provides the following information in relation to the request:

1. The voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose.
2. The Company requests that the voluntary suspension remains in place until the earlier of commencement of normal trading on Monday, 28 August 2023, or when the announcement regarding the stated purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Monday, 28 August 2023.
4. The Company is not aware of any reason why the voluntary suspension should not be granted or of any further information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

Yours sincerely,



Melanie Leydin
Company Secretary



About Avecho

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock.

See more here - avecho.com.au